Nabil F Saba, Nader G Zalaquett, Saad Rashid, Karthik N Rao, Robert P Takes, Carol Bradford, Remco de Bree, Jonathan J Beitler, Arlene A Forastiere, Jan B Vermorken, Anthea L Hammond, Yong Teng, Nicole C Schmitt, Alfio Ferlito
{"title":"免疫治疗时代的头颈部肿瘤手术:综述。","authors":"Nabil F Saba, Nader G Zalaquett, Saad Rashid, Karthik N Rao, Robert P Takes, Carol Bradford, Remco de Bree, Jonathan J Beitler, Arlene A Forastiere, Jan B Vermorken, Anthea L Hammond, Yong Teng, Nicole C Schmitt, Alfio Ferlito","doi":"10.1001/jamaoto.2025.3204","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Head and neck squamous cell carcinoma (HNSCC) is a challenging malignant condition associated with significant morbidity and mortality. Salvage surgery, in addition to other available treatment modalities, constitutes an important therapeutic intervention for locoregionally recurrent HNSCC, offering the potential for improved locoregional control and survival outcomes. However, the indications for salvage surgery remain diverse and poorly standardized, with reported 5-year survival outcome rates ranging from 10% to 61%. In recent years, the incorporation of immunotherapy into the management of recurrent and locally advanced HNSCC has shown promising potential. Although preoperative immunotherapy has resulted in improved outcomes in other malignant neoplasms, such as non-small cell lung cancer, its integration into HNSCC surgical protocols whether in the primary or salvage setting is still in its early stages. Early single-institution trials suggest combining immunotherapy with salvage surgery may enhance survival, reduce recurrence rates, and improve other outcomes for patients with recurrent or persistent HNSCC.</p><p><strong>Observations: </strong>This review explores the evolving landscape of HNSCC salvage surgery in the era of immunotherapy by assessing current evidence, clinical implications, and future directions for this integrated approach.</p><p><strong>Conclusions and relevance: </strong>Advances in immunotherapy and the development of future clinical trials incorporating immunotherapy in the HNSCC salvage setting have the potential to enhance patient selection and optimize surgical outcomes.</p>","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond: A Review.\",\"authors\":\"Nabil F Saba, Nader G Zalaquett, Saad Rashid, Karthik N Rao, Robert P Takes, Carol Bradford, Remco de Bree, Jonathan J Beitler, Arlene A Forastiere, Jan B Vermorken, Anthea L Hammond, Yong Teng, Nicole C Schmitt, Alfio Ferlito\",\"doi\":\"10.1001/jamaoto.2025.3204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Head and neck squamous cell carcinoma (HNSCC) is a challenging malignant condition associated with significant morbidity and mortality. Salvage surgery, in addition to other available treatment modalities, constitutes an important therapeutic intervention for locoregionally recurrent HNSCC, offering the potential for improved locoregional control and survival outcomes. However, the indications for salvage surgery remain diverse and poorly standardized, with reported 5-year survival outcome rates ranging from 10% to 61%. In recent years, the incorporation of immunotherapy into the management of recurrent and locally advanced HNSCC has shown promising potential. Although preoperative immunotherapy has resulted in improved outcomes in other malignant neoplasms, such as non-small cell lung cancer, its integration into HNSCC surgical protocols whether in the primary or salvage setting is still in its early stages. Early single-institution trials suggest combining immunotherapy with salvage surgery may enhance survival, reduce recurrence rates, and improve other outcomes for patients with recurrent or persistent HNSCC.</p><p><strong>Observations: </strong>This review explores the evolving landscape of HNSCC salvage surgery in the era of immunotherapy by assessing current evidence, clinical implications, and future directions for this integrated approach.</p><p><strong>Conclusions and relevance: </strong>Advances in immunotherapy and the development of future clinical trials incorporating immunotherapy in the HNSCC salvage setting have the potential to enhance patient selection and optimize surgical outcomes.</p>\",\"PeriodicalId\":14632,\"journal\":{\"name\":\"JAMA otolaryngology-- head & neck surgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA otolaryngology-- head & neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaoto.2025.3204\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA otolaryngology-- head & neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoto.2025.3204","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond: A Review.
Importance: Head and neck squamous cell carcinoma (HNSCC) is a challenging malignant condition associated with significant morbidity and mortality. Salvage surgery, in addition to other available treatment modalities, constitutes an important therapeutic intervention for locoregionally recurrent HNSCC, offering the potential for improved locoregional control and survival outcomes. However, the indications for salvage surgery remain diverse and poorly standardized, with reported 5-year survival outcome rates ranging from 10% to 61%. In recent years, the incorporation of immunotherapy into the management of recurrent and locally advanced HNSCC has shown promising potential. Although preoperative immunotherapy has resulted in improved outcomes in other malignant neoplasms, such as non-small cell lung cancer, its integration into HNSCC surgical protocols whether in the primary or salvage setting is still in its early stages. Early single-institution trials suggest combining immunotherapy with salvage surgery may enhance survival, reduce recurrence rates, and improve other outcomes for patients with recurrent or persistent HNSCC.
Observations: This review explores the evolving landscape of HNSCC salvage surgery in the era of immunotherapy by assessing current evidence, clinical implications, and future directions for this integrated approach.
Conclusions and relevance: Advances in immunotherapy and the development of future clinical trials incorporating immunotherapy in the HNSCC salvage setting have the potential to enhance patient selection and optimize surgical outcomes.
期刊介绍:
JAMA Otolaryngology–Head & Neck Surgery is a globally recognized and peer-reviewed medical journal dedicated to providing up-to-date information on diseases affecting the head and neck. It originated in 1925 as Archives of Otolaryngology and currently serves as the official publication for the American Head and Neck Society. As part of the prestigious JAMA Network, a collection of reputable general medical and specialty publications, it ensures the highest standards of research and expertise. Physicians and scientists worldwide rely on JAMA Otolaryngology–Head & Neck Surgery for invaluable insights in this specialized field.